Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project.

Willemse EAJ, van Maurik IS, Tijms BM, Bouwman FH, Franke A, Hubeek I, Boelaarts L, Claus JJ, Korf ESC, van Marum RJ, Roks G, Schoonenboom N, Verwey N, Zwan MD, Wahl S, van der Flier WM, Teunissen CE.

Alzheimers Dement (Amst). 2018 Sep 12;10:563-572. doi: 10.1016/j.dadm.2018.08.006. eCollection 2018.

2.

Method comparison study of the Elecsys® β-Amyloid (1-42) CSF assay versus comparator assays and LC-MS/MS.

Shaw LM, Hansson O, Manuilova E, Masters CL, Doecke JD, Li QX, Rutz S, Widmann M, Leinenbach A, Blennow K.

Clin Biochem. 2019 May 23. pii: S0009-9120(19)30488-6. doi: 10.1016/j.clinbiochem.2019.05.006. [Epub ahead of print]

3.

Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging.

Schindler SE, Gray JD, Gordon BA, Xiong C, Batrla-Utermann R, Quan M, Wahl S, Benzinger TLS, Holtzman DM, Morris JC, Fagan AM.

Alzheimers Dement. 2018 Nov;14(11):1460-1469. doi: 10.1016/j.jalz.2018.01.013. Epub 2018 Mar 2.

4.

Derivation of cutoffs for the Elecsys® amyloid β (1-42) assay in Alzheimer's disease.

Shaw LM, Waligorska T, Fields L, Korecka M, Figurski M, Trojanowski JQ, Eichenlaub U, Wahl S, Quan M, Pontecorvo MJ, Lachno DR, Talbot JA, Andersen SW, Siemers ER, Dean RA.

Alzheimers Dement (Amst). 2018 Aug 11;10:698-705. doi: 10.1016/j.dadm.2018.07.002. eCollection 2018.

5.

Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid.

Lifke V, Kollmorgen G, Manuilova E, Oelschlaegel T, Hillringhaus L, Widmann M, von Arnim CAF, Otto M, Christenson RH, Powers JL, Shaw LM, Hansson O, Doecke JD, Li QX, Teunissen C, Tumani H, Blennow K.

Clin Biochem. 2019 May 23. pii: S0009-9120(19)30492-8. doi: 10.1016/j.clinbiochem.2019.05.005. [Epub ahead of print]

6.

Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ42 and T-Tau assays for Alzheimer's disease diagnosis.

Bayart JL, Hanseeuw B, Ivanoiu A, van Pesch V.

J Neurol. 2019 Jun 10. doi: 10.1007/s00415-019-09418-6. [Epub ahead of print]

PMID:
31179518
7.

Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols.

Wang MJ, Yi S, Han JY, Park SY, Jang JW, Chun IK, Giau VV, Bagyinszky E, Lim KT, Kang SM, An SS, Park YH, Youn YC, Kim S.

J Alzheimers Dis. 2016 May 6;52(4):1403-13. doi: 10.3233/JAD-160143.

PMID:
27163824
8.

Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.

Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, Owenius R, Hägerström D, Wollmer P, Minthon L, Hansson O.

JAMA Neurol. 2014 Oct;71(10):1282-9. doi: 10.1001/jamaneurol.2014.1358.

PMID:
25155658
9.

CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts.

Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, Lifke V, Corradini V, Eichenlaub U, Batrla R, Buck K, Zink K, Rabe C, Blennow K, Shaw LM; Swedish BioFINDER study group; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2018 Nov;14(11):1470-1481. doi: 10.1016/j.jalz.2018.01.010. Epub 2018 Mar 1.

10.

Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.

Doecke JD, Rembach A, Villemagne VL, Varghese S, Rainey-Smith S, Sarros S, Evered LA, Fowler CJ, Pertile KK, Rumble RL, Trounson B, Taddei K, Laws SM, Macaulay SL, Bush AI, Ellis KA, Martins R, Ames D, Silbert B, Vanderstichele H, Masters CL, Darby DG, Li QX, Collins S; AIBL Research Group.

J Alzheimers Dis. 2018;61(1):169-183. doi: 10.3233/JAD-170128.

PMID:
29171991
11.

Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine.

Chiasserini D, Biscetti L, Farotti L, Eusebi P, Salvadori N, Lisetti V, Baschieri F, Chipi E, Frattini G, Stoops E, Vanderstichele H, Calabresi P, Parnetti L.

J Alzheimers Dis. 2016 Jul 22;54(1):55-67. doi: 10.3233/JAD-160298.

PMID:
27447425
12.

Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.

Li QX, Villemagne VL, Doecke JD, Rembach A, Sarros S, Varghese S, McGlade A, Laughton KM, Pertile KK, Fowler CJ, Rumble RL, Trounson BO, Taddei K, Rainey-Smith SR, Laws SM, Robertson JS, Evered LA, Silbert B, Ellis KA, Rowe CC, Macaulay SL, Darby D, Martins RN, Ames D, Masters CL, Collins S; AIBL Research Group.

J Alzheimers Dis. 2015;48(1):175-87. doi: 10.3233/JAD-150247.

PMID:
26401938
13.

Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia.

Álvarez I, Aguilar M, González JM, Ysamat M, Lorenzo-Bosquet C, Alonso A, Tartari JP, Romero S, Diez-Fairen M, Carcel M, Pujalte F, Pastor P.

J Alzheimers Dis. 2018;61(1):135-143. doi: 10.3233/JAD-170753.

PMID:
29154286
14.

Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's Disease.

Pan C, Korff A, Galasko D, Ginghina C, Peskind E, Li G, Quinn J, Montine TJ, Cain K, Shi M, Zhang J.

J Alzheimers Dis. 2015;45(3):709-19. doi: 10.3233/JAD-143099.

15.

Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort.

Zwan M, van Harten A, Ossenkoppele R, Bouwman F, Teunissen C, Adriaanse S, Lammertsma A, Scheltens P, van Berckel B, van der Flier W.

J Alzheimers Dis. 2014;41(3):801-7. doi: 10.3233/JAD-132561.

PMID:
24705549
16.

A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging.

Mo Y, Stromswold J, Wilson K, Holder D, Sur C, Laterza O, Savage MJ, Struyk A, Scheltens P, Teunissen CE, Burke J, Macaulay SL, Bråthen G, Sando SB, White LR, Weiss C, Cowes A, Bush MM, DeSilva G, Darby DG, Rainey-Smith SR, Surls J, Sagini E, Tanen M, Altman A, Luthman J, Egan MF.

Alzheimers Dement (Amst). 2017 Mar 6;6:201-209. doi: 10.1016/j.dadm.2017.02.004. eCollection 2017.

17.

Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes.

van Waalwijk van Doorn LJ, Gispert JD, Kuiperij HB, Claassen JA, Arighi A, Baldeiras I, Blennow K, Bozzali M, Castelo-Branco M, Cavedo E, Emek-Savaş DD, Eren E, Eusebi P, Farotti L, Fenoglio C, Ormaechea JF, Freund-Levi Y, Frisoni GB, Galimberti D, Genc S, Greco V, Hampel H, Herukka SK, Liu Y, Lladó A, Lleó A, Nobili FM, Oguz KK, Parnetti L, Pereira J, Picco A, Pikkarainen M, de Oliveira CR, Saka E, Salvadori N, Sanchez-Valle R, Santana I, Scarpini E, Scheltens P, Soininen H, Tarducci R, Teunissen C, Tsolaki M, Urbani A, Vilaplana E, Visser PJ, Wallin AK, Yener G, Molinuevo JL, Meulenbroek O, Verbeek MM.

J Alzheimers Dis. 2017;56(2):543-555. doi: 10.3233/JAD-160668.

PMID:
28059783
18.

Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer's Disease.

Almdahl IS, Lauridsen C, Selnes P, Kalheim LF, Coello C, Gajdzik B, Møller I, Wettergreen M, Grambaite R, Bjørnerud A, Bråthen G, Sando SB, White LR, Fladby T.

Front Aging Neurosci. 2017 Feb 7;9:9. doi: 10.3389/fnagi.2017.00009. eCollection 2017.

19.

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease.

Henjum K, Almdahl IS, Årskog V, Minthon L, Hansson O, Fladby T, Nilsson LN.

Alzheimers Res Ther. 2016 Apr 27;8(1):17. doi: 10.1186/s13195-016-0182-1.

20.

Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.

Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, Dallob A, Chappell D, Snyder K, Flynn M, Simon A, Modur V, Potter WZ, Wilcock G, Savage MJ, Smith AD.

J Alzheimers Dis. 2015;44(2):525-39. doi: 10.3233/JAD-141725.

PMID:
25391385

Supplemental Content

Support Center